Switch View
© Globe Newswire
20.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
News Preview
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for el...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: NL0010583399
Corbion NV
CRBN
LISTED
EURONEXT
Corbion reports the progress of its share buyback program 13 October – 17 October 2025
News Preview
Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
News Preview
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
20.10.2025
ISIN: FR0000121147
Forvia SE
EO
LISTED
EURONEXT
2025 Q3 Sales: Revenue of €6.1 Billion, Stable on an Organic Basis. Strong Financial Discipline. 2025 Guidance Confirmed
News Preview
NANTERRE (FRANCE) OCTOBER 20, 2025...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
20.10.2025
ISIN: CNE1000062J1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990
LISTED
HKSE
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
News Preview
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US09857L1089
Booking Holdings Inc
BKNG
LISTED
NASDAQ
Agoda and Premier Inn Partner to Capture Rising Asian Traveler Interest in UK and Europe
News Preview
The partnership aims to connect travelers from Asia and beyond to over 900 properties across the UK, Germany and Ireland
SINGAPORE, Oct. 20, 2025 /PRNewswire/ -- Global digital travel platform Agoda has announced a new partnership with the United Kingdom's (UK)...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: CNE1000062J1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990
LISTED
HKSE
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
News Preview
CHENGDU, China , Oct. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: INE267A01025
Hindustan Zinc Ltd
HINDZINC
LISTED
BSE
Hindustan Zinc Achieves Highest Ever 2Q Revenue and EBITDA; PAT Surges 19% QoQ
News Preview
UDAIPUR, India, Oct. 20, 2025 /PRNewswire/ -- India based Hindustan Zinc Limited, a Vedanta Group company and the world's largest integrated zinc producer, announced its financial results on 17th October 2025 for the second quarter and half year ended 30th September 2025.The company reported its best-ever second...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
If you suffered losses in Baxter between February 23, 2022 and July 30, 2025 and would...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG039571008
Antengene Corporation Limited
6996
LISTED
HKSE
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
News Preview
SHANGHAI and HONG KONG, Oct. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and so...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KR7091810002
Twayair
091810
LISTED
KOE
Save Now, Travel through March: T'way Air Announces Fall Savings to Korea
News Preview
Promo Code FLYOCT & Special
Coupons
for Travel through March 2026
TAIPEI, Oct. 20, 2025 /PRNewswire/ -- T'way Air, Korea's leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG039571008
Antengene Corporation Limited
6996
LISTED
HKSE
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
News Preview
SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and so...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.10.2025
ISIN: KYG1996C1006
CARsgen Therapeutics Holdings Limited
2171
LISTED
HKSE
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
News Preview
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous C...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
News Preview
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.
- The ultra-long-acting SQ de...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG2588M1006
Cstone Pharmaceuticals
2616
LISTED
HKSE
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
News Preview
SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary P...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
News Preview
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.
- The ultra-long-acting SQ de...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.10.2025
ISIN: CA88900N1050
Tocvan Ventures Corp.
TOC
LISTED
CSE
Tocvan Advances Drilling, Trenching, and Pilot Mine Preparation, Mobilizing Equipment to North and South Blocks at Gran Pilar Gold-Silver Project
News Preview
CALGARY, AB / ACCESS Newswire / October 20, 2025 / Tocvan Ventures Corp. ("Tocvan" or the "Company") (CSE:TOC)(OTCQB:TCVNF)(WKN:TV3/A2PE64), is pleased to announce the mobilization of equipment to both the North and South Blocks of its flagship Gran Pilar Gold-Silver Project in Sonora, Mexico. This marks a significant step forwa...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.10.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Recognition of Patentability of Claims
News Preview
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SE...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: JP3942400007
Astellas Pharma Inc
45030
LISTED
XJPX
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
News Preview
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area
Study results found no new safety signals and no cases of retinal vasculitis or occlu...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US03969F1093
Arcus Biosciences Inc
RCUS
LISTED
NYSE
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
News Preview
Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain o...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US5024311095
L3Harris Technologies, Inc.
LHX
LISTED
NYSE
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
News Preview
L3Harris Technologies (NYSE: LHX) has received a contract to deliver modified Bombardier Global 6500 airborne early warning and control (AEW&C) aircraft to the Republic of Korea Air Force. L3Harris is partnering with Bombardier, Israel Aerospace Industries’ ELTA Systems and Korean Air to provide this advanced capability. The program is valued...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG2280A1076
Clover Biopharmaceuticals, Ltd.
2197
LISTED
HKSE
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
News Preview
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG9572D1034
Webull Corporation
BULL
LISTED
NASDAQ
Webull Reduces Minimum ASX Trading Fee To $1
News Preview
Webull Australia now offers the lowest-cost CHESS-sponsored brokerage fee minimums for trading ASX shares
The new pricing structure is paired with Webull's industry-leading technology and free live pricing data
$1.00 minimum fees will be made available to Australian cli...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: US5907171046
Mesoblast Ltd (ADR)
MESO
LISTED
NASDAQ
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
News Preview
Activity Report for Quarter Ended September 30, 2025 (Appendix 4C) Activity Report for Quarter Ended September 30, 2025 (Appendix 4C)...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: US3073598852
Faraday Future Intelligent Electric Inc
FFAI
LISTED
NASDAQ
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The Whole FX Team is Now in Full Sprint Mode for the Year-End Off-Line Target for the Company’s First FX Super One Vehicle
News Preview
LOS ANGELES, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF....
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: IL0011725277
RZR
LISTED
TLV
Razor Labs Expands Predictive Maintenance Coverage in Australia with Mobile Fleet AI Solution Launch at IMARC 2025
News Preview
The company introduces its proven Mobile Fleet Predictive Maintenance solution to Australia, completing its full-suite offering for mining reliability.
SYDNEY, Oct. 19, 2025 /PRNewswire/ -- Razor Labs (TASE: RZR), a global leader in AI-driven predictive maintenance for the mining industry, today a...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: FR0000120321
L'Oreal SA
OR F
LISTED
EURONEXT
Kering and L’oréal Forge an Alliance in Beauty and Wellness
News Preview
KERING AND L’ORÉAL FORGE AN ALLIANCE IN BEAUTY AND WELLNESS...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: FR0000121485
Kering SA
KER
LISTED
EURONEXT
Kering and L’Oréal forge an alliance in beauty and wellness
News Preview
Press release - Kering and L'Oréal forge a beauty alliance - 20251019...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.10.2025
ISIN: DE0005194062
BayWa AG
BYW6
LISTED
XETR
BayWa AG verhandelt mit neuem Investor über Cefetra-Erwerb. First Dutch an Finanzierung gescheitert. Angebot für die zweite Tranche der Bezugsrechtsbarkapitalerhöhung im Oktober geplant.
News Preview
BayWa verhandelt mit neuem Investor über Cefetra-Erwerb. First Dutch an Finanzierung gescheitert. Angebot für die zweite Tranche der Bezugsrechtsbarkapitalerhöhung im Oktober geplant.
Die BayWa AG geht nicht mehr davon aus, dass der Verkauf der Cefetra Group B.V. („Cefetra“) mit den Unternehmen der First Dutch Group, die den Vertrag über den Erwer......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.10.2025
ISIN: DE0005194062
BayWa AG
BYW6
LISTED
XETR
BayWa AG negotiates with new investor to acquire Cefetra. First Dutch failed to secure financing. Offer of the second tranche of the cash capital increase with subscription rights planned in October
News Preview
BayWa negotiates with new investor to acquire Cefetra. First Dutch failed to secure financing. Offer of the second tranche of the cash capital increase with subscription rights planned in October
BayWa AG no longer assumes that the sale of Cefetra Group B.V. (“Cefetra”) will be closed with the entities of the First Dutch Group, controlled by the Du......
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3156161024
F5 Inc
FFIV
LISTED
NASDAQ
F5, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FFIV
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of F5, Inc. (“F5” or “the Company”) (NASDAQ: FFIV) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On October...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3580391056
Freshpet Inc
FRPT
LISTED
NASDAQ
Freshpet, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FRPT
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Freshpet, Inc. (“Freshpet” or “the Company”) (NASDAQ: FRPT) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors....
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
News Preview
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (P...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3156161024
F5 Inc
FFIV
LISTED
NASDAQ
FFIV Investors Have Opportunity to Join F5, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of F5, Inc. (“F5” or “the Company”) (NASDAQ: FFIV) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose informa...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3580391056
Freshpet Inc
FRPT
LISTED
NASDAQ
FRPT Investors Have Opportunity to Join Freshpet, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Freshpet, Inc. (“Freshpet” or “the Company”) (NASDAQ: FRPT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: US83304A1060
Snap Inc
SNAP
LISTED
NYSE
Snap Inc. Deadline: SNAP Investors Have Opportunity to Lead Snap Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 19, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE: SNAP) betwee...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US1729674242
Citigroup Inc
C
LISTED
NYSE
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
News Preview
American Airlines, Citi and Mastercard today unveiled the Citi® / AAdvantage® Globe™ Mastercard®—a new entry in the travel credit card market that reimagines what mid-tier means with access to premium benefits. Designed to maximize the travel journey, the Citi® / AAdvantage® Globe™ Mastercard® offers four Admirals Club® Globe™ passes, each valid f...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
NEW YORK, Oct. 19, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) and certain of its officers....
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
News Preview
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: BMG9551V1081
Vantage Drilling International
VDI
LISTED
OSL
Vantage Drilling International Ltd. – Announcement of Contract Termination
News Preview
Dubai, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Vantage Drilling International Ltd. (the "Company”) announces the immediate termination of the contract for the Platinum Explorer for its approximately 260-day campaign. The termination is due to changes in economic sanctions applicable to the campaign, rendering the contract execution unlawful and therefo...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
News Preview
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001.
The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therap...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.10.2025
ISIN: US9115491030
United States Antimony Corporation
UAMY
LISTED
XASE
United States Antimony Corporation Submits Indicative Proposal to Acquire 100% of Larvotto Resources Limited Located in Australia
News Preview
Business Combination Would Produce One of the World's Largest Antimony Producers Outside of China"The Critical Minerals and ZEO Company"~ Antimony, Cobalt, Tungsten, and Zeolite ~ DALLAS, TEXAS / ACCESS Newswire / October 19, 2025 / United States Antimony Corporation ("USAC," "US Antimony," or the "Company"),...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as par...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
News Preview
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients
New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across addi...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: IL0011685588
Max Stock Ltd.
MAXO
LISTED
TLV
Max Stock Limited releases an immediate report on holdings of interested parties and senior officers as of September 30, 2025
News Preview
Regulations 33(c)-(d) of the Securities Regulations (Periodic and Immediate Reports), 1970
CAESAREA, Israel, Oct. 19, 2025 /PRNewswire/ -- Max Stock Limited (TASE: MAXO) (the "Company") today announced holdings of interested parties and senior officers as of September 30, 2025:
A....
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
News Preview
Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising clinical activity in patients with previously treated advanced solid tumors refractory to standard treatment. These data were presented today during a proffered paper session (917O) at the 2025 European Society for Medical Oncology...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
News Preview
Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in a...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: GB00BYYW9G87
Avacta Group Plc
AVCT
LISTED
AIMX
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
News Preview
Avacta Therapeutics announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000)....
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US0463531089
AstraZeneca PLC
AZN
LISTED
NASDAQ
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
News Preview
Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: US75382E1091
RAPT Therapeutics, Inc.
RAPT
LISTED
NASDAQ
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.10.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
News Preview
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the Euro...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US2183521028
Corcept Therapeutics Inc
CORT
LISTED
NASDAQ
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
News Preview
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacoril...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
News Preview
Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also kn...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US92337C1045
Verastem Inc
VSTM
LISTED
NASDAQ
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
News Preview
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and safety data from partner GenFleet Therapeutics’ Phase 1/2 monotherapy study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor (VS-7375 outside of...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 mon...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
News Preview
Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for p...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-neg...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
